MEDI:GATE NEWS Daewoong Pharmaceutical’s patent lawsuit against generic sales…imposed a fine of 2.297 billion won
Medytox acquires shares of Daewoong Pharmaceutical’s U.S. partner Evolu, becoming the second largest shareholder
Daewoong Pharmaceutical, operating profit of 17 billion won last year… 62% decrease from the previous year
[금일 제약업계 주요기사] Celltrion antibody treatment’approved’… Bukwang Pharmaceutical “Corona 19 treatment, clinical phase 2 IND approval by the US FDA, etc.
Daewoong Pharmaceutical and LSK Global PS”Fight Son’ and Covid-19 treatment joint clinical development cooperation
Daewoong Pharmaceutical’s’Hoystar tablet’ approved for phase 3 clinical trials for COVID-19 prevention effect